Methods to identify and characterize developmental neurotoxicity for human health risk assessment: overview. by Mileson, B E & Ferenc, S A
Environmental Health Perspectives • VOLUME 109 | SUPPLEMENT 1 | March 2001 77
In 1991, the U.S. Environmental Protection
Agency (U.S. EPA) issued a standardized pro-
tocol for evaluation of developmental neuro-
toxicity (DNT) for use in human health risk
assessment (1). Brieﬂy, the protocol comprises
a) tests for evidence of deﬁcits in neurobehav-
ioral functions including auditory startle,
habituation, associative learning and memory;
b) monitoring of motor activity; and c) neu-
ropathologic examination including simple
morphometric analysis. An analysis of 12
developmental neurotoxicity studies submitted
to the U.S. EPA led to identiﬁcation of several
issues to be considered in an effort to improve
the protocol (2,3). These issues included the
appropriate route of neurotoxicant administra-
tion; the duration of treatment and dosing lev-
els of pups; potential use of pharmacokinetic
data to support developmental neurotoxicity
studies; the role and efﬁcacy of morphometric
data in evaluation of developmental neurotoxi-
city; the efﬁcacy of current studies in evaluat-
ing age-related susceptibility; interpretation of
behavioral data; and identiﬁcation of biologic
marker(s) of pup exposure and/or effect. 
The U.S. EPA intends to revise the Ofﬁce
of Prevention, Pesticides and Toxic Substances
developmental neurotoxicity guidelines in the
near future and expects to address the above
issues in the process. In addition, the
Organisation for Economic Co-operation and
Development has been reﬁning new guidelines
for DNT testing (4). In this context, these and
other scientiﬁc issues important to characteriz-
ing developmental neurotoxicity for human
health risk assessment must be considered. The
International Life Sciences Institute (ILSI)
Risk Science Institute (RSI) (5) entered into a
cooperative agreement with the Office of
Pesticide Programs of the U.S. EPA to address
some of the difficult issues listed above. RSI
convened a working group of experts (6) in
developmental neurobiology, neuropathology,
neurotoxicology, and neuropharmacology
from government, industry, academia, and the
public interest sector to consider the scientiﬁc
basis of the aforementioned issues. 
Summary
Developmental neurotoxicity is any effect of a
toxicant on the developing nervous system
before or after birth that interferes with
normal nervous system structure or function.
Developmental neurotoxicology is both a
basic science, wherein toxicants are used as
tools to increase our understanding of devel-
opmental neurobiology, and an applied sci-
ence, wherein data are generated to address
questions about risk and sensitivity. The lat-
ter neurotoxicology studies are conducted to
identify or characterize potential developmen-
tal neurotoxicity of speciﬁc chemicals on lab-
oratory animals, and the data are then used in
human health risk assessment. Risk assess-
ment of a developmental neurotoxicant
requires careful consideration of the end
point of toxicity, the dose–response relation-
ship, and the relevance of the animal model
to humans. This might require data from
behavioral, neuropathologic and pharmaco-
logic components of developmental neuro-
toxicity studies. The methods and techniques
used in developmental neurotoxicology
studies are being continually reﬁned and will
depend on the questions to be addressed and
the goals of the study. This introductory
article sets the stage for the three following
articles that describe methods used to charac-
terize developmental neurotoxicity, the state
of the science of applied developmental
neurotoxicology, and the strengths and weak-
nesses of various methods and techniques. 
State-of-the-science developmental
neurotoxicology studies focus on the effects
of toxicants on particular structures and
functions of the developing nervous system,
using laboratory animals as a surrogate for
the human. The mammalian central and
peripheral nervous systems are complex
structures resulting from essential develop-
mental processes including cell proliferation,
differentiation, migration, synaptogenesis,
and myelination [for example, see Bayer et
al. (7) and Rice and Barone (8)]. These
stages of development normally occur
sequentially according to different temporal
profiles within specific regions of the brain
and result in a heterogeneous pattern of
synaptic connectivity. Integration of the con-
nections formed and stabilized during brain
development depends on a process of reﬁne-
ment and selective consolidation of the
neural circuitry. This process begins during
gestation and continues postnatally through
adolescence. Critical windows of vulnerabil-
ity in the developing nervous system must be
considered in neurotoxicity testing (9). These
critical windows are dependent, for example,
on the developmental stage of the target tis-
sue or nervous system component, the mech-
anism of action of the toxic agent, the dose of
the agent delivered to the target tissue, the
toxic end point of interest, the age of the off-
spring during testing, and the method used to
evaluate the outcome. The desire of investiga-
tors to maximize the likelihood of detecting an
adverse effect on the nervous system in toxicity
studies has led an impetus to evaluate multiple
end points of toxicity at multiple times and
dosing levels during pre- and postnatal devel-
opment. However, an attempt to account for
all possible end points and windows of vulner-
ability in a single experiment can lead to an
unmanageable experimental design. The
potential problems associated with an overly
complex experimental design must be weighed
against the possibility that inadequate
evaluation might fail to identify a significant
developmental neurotoxicant effect. 
The ILSI RSI working group was asked
to identify and describe sensitive yet practical
methods to detect and/or characterize devel-
opmental neurotoxicity in laboratory ani-
mals. The working group separated into
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three breakout groups, each to focus on a
specific area in their discussions of develop-
mental neurotoxicity: behavioral testing,
neuropathology, and pharmacokinetics.
Several of the key scientific and technical
challenges to evaluation of developmental
neurotoxicity addressed by the breakout
groups are summarized below. 
The breakout group on behavioral testing
considered the alterations in nervous system
function that may be identiﬁed in laboratory
animals, using neurobehavioral methods
(10). Careful consideration in experimental
design is key to the success of studies that
rely on behavioral methods to evaluate devel-
opmental neurotoxicity. Neurobehavioral
assessment methods are used routinely to
evaluate the effects of developmental neuro-
toxicants on sensory function, motor func-
tion, and cognitive function. Guiding
principles for proper use and interpretation
of neurobehavioral methods are essential for
scientists who conduct or evaluate develop-
mental neurotoxicity studies. Fundamental
issues that underlie proper use and interpre-
tation of these methods include a) considera-
tion of the scientific goal in experimental
design, b) selection of an appropriate animal
model, c) the expertise of the investigator, d)
adequate statistical analysis, and e) proper
data interpretation. The appropriate behav-
ioral test methods are selected on the basis of
study goals and objectives. Considerations in
method selection include the sensitivity
required to detect a given effect, the selectiv-
ity required to identify or characterize an
effect, available resources, and the inherent
variability in the methods. 
The neuropathology breakout group
addressed the approaches used in morpho-
logic and histopathologic assessment of toxi-
cant-induced alterations in the developing
nervous system for human health risk assess-
ment (11). Morphologic assessment of the
developing brain requires an understanding
of corresponding timeframes for the critical
events in nervous system development of the
rat and human. This global spatial–temporal
map, together with an understanding of the
pathogenesis of nervous system malforma-
tions, can guide the pathologist in the identi-
ﬁcation and interpretation of toxicant-related
effects (6). Two considerations are central to
the morphologic identification of adverse
effects. One is that normal developmental
events such as programmed cell death must
be distinguished from treatment-related
effects that may exhibit similar morphologic
characteristics. A second consideration is that
disruption of relatively early developmental
events can alter growth and differentiation,
thus resulting in alterations in the size of
neuroanatomic structures. Quantitative mor-
phologic evaluation of developmental neuro-
toxicant effects can include a variety of
techniques, from simple determination of
brain weight and dimensions, to the progres-
sively more complex approaches of linear,
areal, or steriologic measurement of brain and
peripheral nervous system sections. Histologic
evaluation employs routine stains (such as
hematoxylin and eosin) that can be comple-
mented by a variety of special staining and
immunohistochemical procedures. These
brain studies are augmented by morphologic
assessment of selected peripheral nervous sys-
tem structures. Studies of this nature require
a high level of technical skill, as well as special
training on the part of the pathologist. 
The breakout group on pharmacologic
testing agreed that pharmacokinetic and phar-
macodynamic factors should be considered in
the design and interpretation of developmen-
tal neurotoxicity studies (12). Many of the
pharmacokinetic methods, analytical chemical
techniques, and modeling approaches needed
to evaluate the pharmacokinetics of a develop-
mental neurotoxicant in the developing
organism are available to the research investi-
gator, though they are not routinely used in
applied studies. Pharmacologic data may
allow an experimenter to determine whether
exposure to the test chemical is adequate,
whether exposure occurs during critical peri-
ods of nervous system development, whether
route and duration of exposure are appropri-
ate, and whether developmental neurotoxicity
can be differentiated from pharmacologic
effects. Physiologically based pharmacokinetic
and pharmacodynamic models can be used to
estimate tissue dose and biologic response fol-
lowing in utero or neonatal exposure.
Application of these models can reduce
uncertainty in the extrapolation of results
from animal studies to humans. 
The following three consensus articles
summarize the discussions and conclusions of
the breakout groups. Methods and techniques
to evaluate the behavioral and pathologic
effects of exposure to toxicants have been
used for many years to characterize develop-
mental neurotoxicity [see U.S. EPA guide-
lines for example (1)]. The pharmacologic
methods now being considered have shorter
history of use in the design and interpretation
of developmental neurotoxicity studies and
are less well established. Consequently, the
articles on behavioral testing and neuro-
pathology focus on proper use of current
methods and techniques, whereas the article
on pharmacokinetics focuses on incorpora-
tion of new methods in developmental neuro-
toxicity testing. These articles should inform
scientists in general and guide professionals
who are not necessarily specialists in all
aspects of developmental neurotoxicology. 
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